The FDA releases revision of guidance regarding Control of Nitrosamine Impurities in Human Drugs
- Home
- regulatory updates
- The FDA releases revision of guidance regarding Control of Nitrosamine Impurities in Human Drugs
The FDA releases revision of guidance regarding Control of Nitrosamine Impurities in Human Drugs
Wednesday, 18 September 2024
Pablo Palomar, Senior Toxicology Officer at QbD Group
Share
\
\
X (Twitter) 
\
\
LinkedIn 
\
\
WhatsApp 
\
\
Copy link 
\
\
Mail
The FDA has just released an updated version of its Control of Nitrosamine Impurities in Human Drugs Guidance, introducing crucial changes for pharmaceutical manufacturers.
Play
The FDA releases revision of guidance regarding Control of Nitrosamine Impurities in Human Drugs | QbD Group
AI-generated audio
1:34
What’s new?
Here are the key updates on the FDA’s revision of the guidance on controlling nitrosamine impurities:
- Renewed focus on Nitrosamine Drug Substance-Related Impurities (NDSRIs): The FDA, aligning with EMA’s strategy, now emphasizes the need to assess not only just small-molecule nitrosamines but also potential NDSRI formation.
- Broader root cause analysis: Expanded causes of nitrosamine formation, with new mitigation strategies like using antioxidants to prevent NDSRI formation.
- Updated Acceptable Intake (AI) limits: Based on the Carcinogenic Potency Categorization Approach (CPCA), including AI limits for drug products at risk of forming NDSRIs and detailed testing recommendations.
- Three-step mitigation strategy: Similar to the EMA’s approach (steps 1, 2, and 3) is now recommended for manufacturers and applicants.
What does this mean to you?
Ongoing risk assessments are now mandatory, with updated safety testing and reformulation strategies to prevent nitrosamine formation. This means that companies must be vigilant in monitoring their products for potential risks and take proactive steps to ensure consumer safety.
How can QbD Group assist you?
Our expert team toxicologist is here to guide you through regulatory changes and ensure your Nitrosamine Risk Assessments are up-to-date and compliant.
Discover more expert content
Previous
Pharma & Biotech
14 May 2024
Latest Update on Appendix 1 of the Nitrosamine Guidelines
On 01/05/2024, the European Medicines Agency (EMA) rolled out an update to Appendix 1...
Pharma & Biotech
27 Jan 2025
New revision to EMA Guidance documents released
Both documents, Guidance on the procedural aspects for the consultation to the European Medicines...
Pharma & Biotech
4 Dec 2025
New Update of Appendix 1 of the Nitrosamines Guideline - EMA/42261/2025/Rev. 11
What's new? This update introduces the Acceptable Intake (AI) values for new nitrosamine drug...
Pharma & Biotech
9 Jul 2024
New Update of Appendix 1 of the Nitrosamines Guideline
What’s new? In this update, the Acceptable Intake (AI) values for nitrosamines related to the use...
Pharma & Biotech
2 Jun 2025
Nitrosamines Update EMA/409815/2020 Rev.22
What is new?
Pharma & Biotech
14 May 2024
Latest Update on Appendix 1 of the Nitrosamine Guidelines
On 01/05/2024, the European Medicines Agency (EMA) rolled out an update to Appendix 1...
Pharma & Biotech
27 Jan 2025
New revision to EMA Guidance documents released
Both documents, Guidance on the procedural aspects for the consultation to the European Medicines...
Pharma & Biotech
4 Dec 2025
New Update of Appendix 1 of the Nitrosamines Guideline - EMA/42261/2025/Rev. 11
What's new? This update introduces the Acceptable Intake (AI) values for new nitrosamine drug...
Pharma & Biotech
9 Jul 2024
New Update of Appendix 1 of the Nitrosamines Guideline
What’s new? In this update, the Acceptable Intake (AI) values for nitrosamines related to the use...
Pharma & Biotech
2 Jun 2025
Nitrosamines Update EMA/409815/2020 Rev.22
What is new?
Pharma & Biotech
14 May 2024
Latest Update on Appendix 1 of the Nitrosamine Guidelines
On 01/05/2024, the European Medicines Agency (EMA) rolled out an update to Appendix 1...
Pharma & Biotech
27 Jan 2025
New revision to EMA Guidance documents released
Both documents, Guidance on the procedural aspects for the consultation to the European Medicines...
Next
- 1
- 2
- 3
Stay ahead in life sciences
Keeping up with the fast-paced life sciences industry doesn’t have to be overwhelming.
Our newsletter delivers the latest insights, industry updates, and expert content directly to your inbox, helping you stay informed and make smarter decisions.
Twitter Widget Iframe